PCSK9 Inhibitors – Does the Benefit Outweigh the Cost?

The results of the GAUSS-3 trial were recently presented at the American College of Cardiology 65th Scientific Session & Expo and were published online in the Journal of the American Medical Association. How did the PCSK9 inhibitor perform among patients with statin intolerance? Was it found to be cost effective? Read more here. (Source: First Report Managed Care, 4/4/16)

You might also be interested in:

ICER Releases Updated Report on Targeted Treatments for Plaque… August 5, 2018
ICER Updates Value-Based Price Benchmark for Alirocumab March 10, 2018
ICER Releases Final Report on CGRP Inhibitors for Migraine Prevention July 5, 2018
ICER Releases Evidence Report on CGRP Inhibitors June 1, 2018
Study: EHRs Could Provide Cost-Effective Means for More… May 25, 2018
ICER Final Report: Emicizumab Boosts Health, Cuts Costs for… April 18, 2018
Studies Reveal Value of Health Wearables March 13, 2018